Brokers Issue Forecasts for ONCY FY2029 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Oncolytics Biotech in a report released on Monday, February 3rd. HC Wainwright analyst P. Trucchio expects that the company will earn $1.10 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.29) per share.

ONCY has been the topic of a number of other research reports. Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th. Leede Financial cut shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th.

Oncolytics Biotech Trading Down 5.3 %

Shares of Oncolytics Biotech stock opened at $0.69 on Tuesday. The business has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.98. Oncolytics Biotech has a 1-year low of $0.67 and a 1-year high of $1.53.

Hedge Funds Weigh In On Oncolytics Biotech

An institutional investor recently raised its position in Oncolytics Biotech stock. International Assets Investment Management LLC grew its position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) by 15.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 200,400 shares of the company’s stock after buying an additional 26,069 shares during the quarter. International Assets Investment Management LLC owned 0.26% of Oncolytics Biotech worth $186,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.